PPARGC1A and cardiomyopathy: In summary, this study described the role of PGC-1α agonist (ZLN005) in mitigating cardiomyopathy phenotype by strengthening the redox balance via mitigating the DOX-mediated oxidative stress, preventing the harmful tissue remodeling effects and necroptosis.